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Abstract
Background: In the central nervous system, astrocytic L-glutamate (L-Glu) transporters maintain extracellular
L-Glu below neurotoxic levels, but their function is impaired with neuroinflammation. Microglia become
activated with inflammation; however, the correlation between activated microglia and the impairment of
L-Glu transporters is unknown.
Methods: We used a mixed culture composed of astrocytes, microglia, and neurons. To quantify L-Glu
transporter function, we measured the extracellular L-Glu that remained 30 min after an application of L-Glu
to the medium (the starting concentration was 100 μM). We determined the optimal conditions of
lipopolysaccharide (LPS) treatment to establish an inflammation model without cell death. We examined the
predominant subtypes of L-Glu transporters and the changes in the expression levels of these transporters in
this inflammation model. We then investigated the role of activated microglia in the changes in L-Glu
transporter expression and the underlying mechanisms in this inflammation model.
Results: Because LPS (10 ng/mL, 72 h) caused a significant increase in the levels of L-Glu remaining but did
not affect cell viability, we adopted this condition for our inflammation model without cell death. GLAST
was the predominant L-Glu transporter subtype, and its expression decreased in this inflammation model. As
a result of their release of L-Glu, activated microglia were shown to be essential for the significant decrease
in L-Glu uptake. The serial application of L-Glu caused a significant decrease in L-Glu uptake and GLAST
expression in the astrocyte culture. The hemichannel inhibitor carbenoxolone (CBX) inhibited L-Glu release
from activated microglia and ameliorated the decrease in GLAST expression in the inflammation model. In
addition, the elevation of the astrocytic intracellular L-Glu itself caused the downregulation of GLAST.
Conclusions: Our findings suggest that activated microglia trigger the elevation of extracellular L-Glu
through their own release of L-Glu, and astrocyte L-Glu transporters are downregulated as a result of the
elevation of astrocytic intracellular L-Glu levels, causing a further increase of extracellular L-Glu. Our data
suggest the new hypothesis that activated microglia collude with astrocytes to cause the elevation of
extracellular L-Glu in the early stages of neuroinflammation.
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Background
L-glutamate (L-Glu) is one of the most important exci-
tatory neurotransmitters in the mammalian central
nervous system (CNS). However, high concentrations
of L-Glu cause excessive stimulation of L-Glu recep-
tors and lead to neurotoxicity [1,2]. In astrocytes,
GLAST (EAAT1 in humans) and GLT-1 (EAAT2) are
the major functional L-Glu transporters in the CNS,
and they play an important role in maintaining extracel-
lular L-Glu concentrations below neurotoxic levels [3].
Impairments of L-Glu transporter function have been
reported in numerous neurological diseases associated
with inflammation, for example, Alzheimer’s disease [4],
amyotrophic lateral sclerosis [5], major depressive dis-
order [6,7], and epilepsy [8-10]. Furthermore, elevated
extracellular L-Glu content has been reported in in vivo
and in vitro inflammation models [11,12]. Accordingly,
the impairment of L-Glu transporters has been suggested
to contribute to elevated extracellular L-Glu concentra-
tions in inflammation; however, the specific role of such
transporters remains unknown, as some inflammation
models also cause cell death.
The CNS is composed of neurons and the following
three types of glial cells: astrocytes, microglia, and oligo-
dendrocytes [13]. Microglia are the primary cells that are
activated in response to inflammatory stimulation
[14,15] and are the resident innate immune cells in the
CNS. Once activated, microglia exhibit a phenotypic
switch from a resting ramified type to a motile amoeboid
type [16,17] and release various soluble factors, includ-
ing pro-inflammatory cytokines [18,19], reactive oxygen
species [20], nitric oxide (NO) [16], L-Glu [21,22], and
ATP [23,24]. Although the direct application of some of
these factors has been reported to inhibit L-Glu trans-
porters [25-28], few studies have examined the inter-
action between activated microglia and astrocyte L-Glu
transporters in inflammation.
In this study, we aimed to clarify the interaction be-
tween activated microglia and astrocyte L-Glu transpor-
ters in inflammation. To quantify L-Glu transporter
function, we measured the extracellular concentrations
of L-Glu (that is, the concentration of L-Glu remaining)
after a single exogenous application of L-Glu to the
medium. To ensure that we measured the effects on live
cells (and not L-Glu released from dying cells), we iden-
tified a condition of lipopolysaccharide (LPS) application
that was suitable to induce inflammation without cell
death. In this model, we found that activated microglia
released L-Glu, the resultant elevation in extracellular
L-Glu led to the elevation of intracellular L-Glu con-
tent in astrocytes through L-Glu transporters, and the
increased level of intracellular L-Glu in astrocytes
decreased GLAST expression. These reactions caused a
further elevation of the extracellular concentration of
L-Glu. Our data suggest a new hypothesis in which
activated microglia collude with astrocytes to cause the
elevation of extracellular L-Glu in the early stages of
neuroinflammation.
Methods
All procedures using live animals in this study were con-
ducted in accordance with the guidelines of the National
Institute of Health Sciences (NIHS), Japan, as developed
under the Guide for the Care and Use of Laboratory
Animals by the National Research Council. Also all
experiments were approved by the ethics committee of
the NIHS.
Materials
L-Glu, LPS, CBX, anti-rabbit Iba-1 polyclonal antibody
(019–19741), and paraformaldehyde (PFA) were purchased
from Wako (Osaka, Japan). Dihydrokainic acid (DHK), ad-
enosine 50-triphosphate disodium salt hydrate (ATP), 20
(30)-O-(4-benzoylbenzoyl)ATP triethylammonium salt
(BzATP), 20,30-O-(2,4,6-trinitrophenyl)ATP salt hydrate
(TNP-ATP), adenosine 50-triphosphate, periodate oxidized
sodium salt (OxATP), poly-L-lysine hydrobromide, poly-
ethylenimine, β-nicotinamide adenine dinucleotide (β-
NAD), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT), 1-methoxy-5-methyl-phenazinium
methyl sulfate (MPMS), Triton-X100, lactate lithium salt,
anti-mouse β-actin monoclonal antibody (A5316), sodium
deoxycholate, 2-mercaptoethanol, bromophenol blue so-
dium salt (BPB), and bovine serum albumin (BSA) were
purchased from Sigma (St Louis, MO, USA). DL-threo-β-
benzyloxyaspartic acid (TBOA) was purchased from
TOCRIS (Ellisville, MO, USA). An MTT Cell proliferation
assay kit was purchased from Life Technologies (Grand Is-
land, NY, USA). Rat glutamate transporter (GLAST/
EAAT1) control peptide (GLAST11-P) and rat glutamate
transporter (GLT1/EAAT2) control peptide (GLT11-P)
were purchased from Alpha Diagnostic (San Antonio, TX,
USA). Clodronate disodium salt and polyoxyethylene (9)
octylphenyl ether (NP-40) were purchased from Calbio-
chem (Darmstadt, Germany). Dulbecco’s modified eagle
medium (DMEM), fetal bovine serum (FBS), and horse
serum (HS) were purchased from GIBCO (Grand Island,
NY, USA). Bovine liver glutamate dehydrogenase (GlDH)
was purchased from Roche (Mannheim, Germany). RNeasy
Mini Kits and an RNase-Free DNase set were purchased
from Qiagen (Hilden, Germany). TaqMan one-step RT-
PCR master mix reagents and TaqMan ribosomal RNA
control reagents (VIC Prove) were purchased from Applied
Biosystems (Foster City, CA, USA). 2-Amino-5,6,7,8-tetra-
hydro-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-4H-
chromene-3-carbonitrile (UCPH-101), rabbit anti-GLAST
polyclonal antibody (ab65978), and anti-chicken glial fibril-
lary acidic protein (GFAP) polyclonal antibody (ab4674)
Takaki et al. Journal of Neuroinflammation 2012, 9:275 Page 2 of 17
http://www.jneuroinflammation.com/content/9/1/275
were purchased from Abcam (Cambridge, UK). Goat
anti-EAAT2 (GLT1) antibody (sc-7760) was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-mouse Tuj1 (β3 tubulin) antibody (MAB5564) was
purchased from Chemicon (Temecula, CA, USA). Donkey
anti-rabbit IgG conjugated with horseradish peroxidase
was purchased from Amersham Biosciences (Washington,
DC, USA). The SuperSignal West Femto Trial Kit was
purchased from Thermo Scientific (Rockford, IL, USA).
The BCA protein assay kit was purchased from Pierce
Chemical (Rockford, IL, USA). Tris (hydroxymethyl) ami-
nomethane (Tris–HCl) was purchased from Bio-Rad
(Hercules, CA, USA). Ethylenediaminetetraacetate (EDTA)
and ethyleneglycoldiaminetetraacetate (EGTA) were pur-
chased from Dojindo (Kumamoto, Japan). Goat serum,
anti-mouse IgG-conjugated Alexa Fluor 488, anti-chicken
IgG-conjugated Alexa Fluor 594, and anti-rabbit IgG-
conjugated Alexa Fluor 647 were purchased from Vector
Laboratories (Burlingame, CA, USA).
Cell culture
Astrocyte-microglia-neuron mixed culture
The brains of 2-day-old Sprague–Dawley (SD) rats were
aseptically removed, and the cerebral cortices were dis-
sected. The tissues were dissociated by trituration and tryp-
sinization. After centrifugation at 1,500 rpm for 5 min, the
cells were suspended in DMEM supplemented with 10%
FBS and 1% antibiotic-antimitotic agent, and the residual
tissue aggregates were removed by filtration through a cell
strainer with a pore size of 40 to 45 μm. The cells were
seeded onto appropriately sized poly-L-lysine-coated plas-
tic dishes or polyethyleneimine-coated cover glass, and
grown for 8 days at 37°C in a humidified atmosphere con-
taining 5% CO2. The medium was changed every 2 days.
Astrocyte culture
The primary culture of rat astrocytes was prepared
according to a method previously described [29,30]. The
cortical cells were obtained by the methods described
above and were seeded in uncoated 75-cm2 flasks at a
density of 5 × 104 cells/cm2. The medium was changed
24 h after plating and then every 3 to 4 days. When the
cells became confluent (10 to 14 days in vitro (DIV)),
the non-astrocyte cells were detached from the flasks by
shaking and removed by changing the medium. The
remaining cells were dissociated by trypsinization and
seeded onto appropriately sized poly-L-lysine-coated
plastic dishes or polyethyleneimine-coated cover glass at
a density of 3 × 105 cells/cm2. The cells became conflu-
ent again 2 to 3 days after plating.
Microglia culture
The primary culture of the rat microglia was prepared
according to a method previously described [31]. In
brief, the cells were obtained from the cerebral cortices
of 1-day-old SD rats and seeded in poly-L-lysine-coated
75-cm2 flasks at a density of 2.5 × 105 cells/cm2. The
cells were then grown in DMEM containing 10% FBS,
10 U/mL penicillin, and 10 mg/mL streptomycin for 10
to 14 days at 37°C. The medium was changed every 2 to
3 days. The microglia were removed from the flask bot-
toms by gentle shaking (60 rpm, 2 min) and collected by
centrifugation at 1,000 × g for 5 min. The microglia were
resuspended and seeded at a density of 6 × 104 cells/cm2
onto appropriately sized poly-L-lysine-coated plastic
dishes or polyethyleneimine-coated cover glass.
Astrocyte-microglia co-culture
The microglia prepared by the methods described above
were seeded at a density of 6 × 104 cells/cm2 onto con-
fluent astrocytes and cultured for 1 to 2 days.
Astrocyte-neuron co-culture
The astrocyte-microglia-neuron co-culture was treated
with clodronate [32] at a concentration of 10 μg/mL for
4 days from 5 DIV to reduce the density of microglia to
below 1.2 × 103 cells/cm2.
Drug treatment
Stock solutions of 100 mM L-Glu, 10 μg/mL LPS,
100 μg/mL clodronate, 10 mM TBOA (non-selective
L-Glu transporter inhibitor, IC50: 48 μM for GLAST,
7 μM for GLT-1), 10 mM UCPH-101 (a GLAST specific
inhibitor, IC50: 0.66 μm for GLAST, >400-fold selectivity
over EAAT2 and EAAT3), 10 mM DHK (a GLT-1-
specific inhibitor, IC50: >3,000 μM for GLAST, 23 μM
for GLT-1), 100 mM ATP, 10 mM BzATP, 10 mM, and
100 mM CBX in phosphate-buffered saline (PBS) were
dissolved into the culture medium at the time of applica-
tion. At 8 DIV, the astrocyte-microglia-neuron culture was
treated with LPS at concentrations of 1 to 100 ng/mL for 6
to 72 h. TBOA, UCPH-101, or DHK was applied to
the astrocyte-microglia-neuron co-culture for 24 h at
10 DIV. ATP or BzATP was applied to the astrocyte
culture at concentrations of 100 to 3,000 μM or 10 to
300 μM, respectively, for 72 h. At 8 DIV, CBX was
applied to the astrocyte-microglia-neuron culture at
concentrations of 10 to 100 μM from 1 h before to
the end of the LPS treatment.
The measurement of the extracellular L-Glu concentration
in the medium
The measurement of L-Glu concentration in the medium
was performed according to a previously described
method [33]. The culture medium in the 96-well plates
was replaced with fresh medium containing 100 μM
L-Glu. After 30 min, 50 μL of the culture medium in
each well was collected. The L-Glu concentration was
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measured by mixing the medium with 50 μL of substrate
mixture (20 U/mL GlDH, 2.5 mg/mL β-NAD, 0.25 mg/mL
MTT, 100 μM MPMS, and 0.1% (vol/vol) Triton X-
100 in 0.2 M Tris–HCl buffer (pH 8.2)) and incubating
the mixture at 37°C for 30 min. The reaction was stopped
by adding 100 μL of stop solution (50% (vol/vol)
dimethylformamide and 20% (wt/vol) sodium dodecyl
sulfate (SDS) in water (pH 4.7)). The amount of the reac-
tion product (MTT formazan) was determined by meas-
uring the absorbance at 570 nm (test wavelength) and
655 nm (reference wavelength) with a microplate reader.
The extracellular L-Glu concentration was estimated
from a standard curve, which was constructed for each
assay using cell-free medium containing known concen-
trations of L-Glu. When the L-Glu was not applied after
washing with fresh medium, no changes in extracellular
L-Glu concentrations were observed in the 30 min incu-
bation period in any experiments in this study. To meas-
ure the L-Glu released from microglia, the extracellular
concentration of L-Glu was measured after 24 h of LPS
treatment. The control values were almost same in the
same culture batch but variable among different batches
(40 to 60 μM). We therefore confirmed the reproducibil-
ity of the results in three independent experiments using
different culture batches.
LDH and MTT assays
The lactate dehydrogenase (LDH) activity in the medium
was evaluated according to a previously described method
[33]. Briefly, 50 μL of culture medium from each well of a
96-well plate was mixed with 50 μL of substrate mixture
(2.5 mg/mL lactate lithium salt, 2.5 mg/mL β-NAD,
0.25 mg/mL MTT, 100 μM MPMS, and 0.1% (vol/vol)
Triton X-100 in 0.2 M Tris–HCl buffer (pH 8.2)). After a
10 min incubation at 37°C, the reaction was stopped by
adding 100 μL of stop solution as described above. The
amount of MTT formazan was determined using a micro-
plate reader. The data were normalized to the aver-
aged value of the group treated with 0.1% (vol/vol)
Triton-X 100 for 1 h. MTT reductions were evaluated
according to the manufacturer’s instructions.
Real-time quantitative polymerase chain reaction
(TaqMan RT-PCR)
The total cellular ribonucleic acid (RNA) was extracted
from cells with an RNeasy Mini Kit and treated with
RNase-free DNase to eliminate genomic deoxyribo-
nucleic acid (DNA) contamination. The amount of total
RNA was quantified by measuring the OD260 using a
Nanodrop spectrophotometer (Nanodrop, Wilmington,
DE). The reactions (25 μL) contained 1 ng of total
RNA, 900 nM forward and reverse primers, 250 nM
TaqMan probe, and RNase inhibitor mix in the master
mix solution. The RT-PCR was performed using the
TaqMan One-Step RT-PCR master mix reagent kit accord-
ing to the manufacturer’s protocol. The data were analyzed
with 7,900 System SDS Software 2.2.2 (Applied Biosystems,
Foster City, CA, USA) using the standard curve method.
The GLAST and GLT-1 mRNA expression levels were nor-
malized to the ribosomal RNA control (18S) expression
levels. The primer sequences were as follows: 5’-GATCGG
CATAATCATTGTCATCA-3’, 5’-CGATTTTACCTTCTC
TGTACATGTTTC-3’ (GLAST), and 5’-CCGAGCTGGA
CACCATTGA-3’ 5’-AATGGACTGCGTCTTGGTCAT-3’
(GLT-1). Specific probes for GLAST (TCCACCCCGG
AAAGGGCACG) and GLT-1 (CAACACCGAATGAATG
CACGAAGACATCGA) were used.
Western blotting
The cells were washed twice with PBS and once with lys-
ate buffer (150 mM (wt/vol) NaCl, 10 mM (wt/vol)
EDTA, 5 mM (wt/vol) EGTA, 0.5% mM (vol/vol) NP-40,
and 0.5% (wt/vol) sodium deoxycholate in 10 mM Tris–
HCl buffer (pH 7.4)). The protein concentration was
measured using the BCA protein assay. The proteins
(20 μg/lane) were mixed with SDS sample buffer (2%
(wt/vol) SDS, 10% (vol/vol) glycerol, 0.25% (wt/vol) BPB,
5% (vol/vol) 2-mercaptoethanol in 125 mM Tris–HCl
buffer (pH 6.8)), loaded onto a 10% polyacrylamide gel,
electrophoresed, and transferred onto a PVDF mem-
brane. The membrane was blocked with 5% (wt/vol)
non-fat dry milk in Tris-buffered saline containing 0.1%
(vol/vol) Tween 20. The membrane was incubated with
rabbit anti-GLAST polyclonal antibody (1:4,000; ab65978,
Abcam), mouse anti GLT-1 (1:2,000; sc-7760, Santa Cruz)
or anti β-actin monoclonal antibody (1:5,000; A5316,
Sigma-Aldrich) overnight at 4°C followed by incubation
with the horseradish peroxidase-conjugated anti-rabbit
antibody (1:20,000; Amersham Biosciences) or the anti-
mouse or anti-goat antibody (1:20,000 Amersham Bios-
ciences). The signals were scanned with an LAS3000 (Fuji
Photo Film Co., Ltd., Tokyo, Japan) using an ECL western
blot detection system (SuperSignal West Femto Trial Kit).
For relative quantification of the expression levels of
GLAST and GLT-1, we first compared the densities of the
bands of the same amount of GLAST and GLT1 control
proteins (full length) (1, 10 μg). In the LPS-exposure ex-
periment, we normalized the band density of each sub-
type to the density of the 10 μg control band of the
corresponding subtype. The bands of GLAST and GLT1
standard proteins were obtained at the same appropriate
exposure time. The bands of GLAST and GLT1 in the
LPS-exposure experiment were obtained at the same ap-
propriate exposure time.
Immunocytochemistry
The cells were washed with PBS three times and fixed
with 4% PFA for 60 min at room temperature. After
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more washes with PBS, the cells were permeabilized and
blocked for 60 min with 0.1% (vol/vol) Triton X-100, 5%
(vol/vol) goat serum, and 1% (wt/vol) BSA in PBS. After
washes with PBS, the cells were incubated with primary
antibodies overnight at 4°C. Mouse monoclonal anti-
Tuj1 antibody (1:500, MAB5564, Chemicon), chicken
polyclonal anti-GFAP antibody (1:400, ab4674, Abcam),
and rabbit polyclonal anti-Iba1 antibody (1:1,000, 019–
19741, Wako) were used to stain neurons, astrocytes,
and microglia, respectively. After washes with PBS, the
cells were incubated with secondary antibodies (1:500,
Invitrogen) conjugated to fluorochromes for 2 h at room
temperature in the dark. After washes with PBS, fluores-
cent images of the cells were obtained by confocal mi-
croscopy (LSM5 Pascal, Zeiss).
Characterization of microglial releasing factors that
downregulate L-Glu transporters
For the conditioned medium study, the astrocyte-
microglia-neuron mixed culture was treated with LPS
(10 ng/mL, 72 h), and the conditioned medium was
transferred to the astrocyte culture. After 72 h, the
L-Glu clearance assay was performed on the astrocyte
culture. In a separate experiment, the astrocyte culture
was incubated for 72 h with a transwell carrying micro-
glia that had been treated with LPS, and the L-Glu clear-
ance assay was performed in the astrocyte culture. For
the serial applications of L-Glu, the medium of the
astrocyte-microglia-neuron mixed cultures was replaced
with fresh medium containing L-Glu (100 μM) every 2 h
for 24 h. The L-Glu clearance assay, TaqMan RT-PCR,
and western blotting were performed after the serial ap-
plication of L-Glu.
The measurement of the astrocytic intracellular L-Glu
concentration
The astrocyte-microglia co-culture was treated with LPS
(10 ng/mL, 72 h) and washed twice with gentle shaking to
remove microglia. After confirmation of the microglial re-
moval under a microscope, 0.1% TritonX-100 was applied
and incubated for 1 h. The L-Glu concentration in the
supernatant was measured as described above. TBOA was
applied from 1 h before the start of LPS treatment.
Statistical analysis
All data are expressed as the mean ± the S.E.M. Statistical
analyses were performed with Student’s t test or a one-
way repeated-measures analysis of variance (ANOVA)
followed by Tukey’s post-hoc test for multiple pairwise
comparisons, as shown in the figure legends. In all of the
comparisons, the differences were considered statistically
significant when P <0.05. All of the experiments were
repeated in triplicate, and the same results were obtained
in all of the sessions.
Results
L-Glu uptake was decreased during inflammation without
cell death through the downregulation of GLAST expression
To definitively investigate the interactions between acti-
vated microglia and astrocytes, we used a mixed culture
composed of astrocytes, microglia, and neurons. To
quantify L-Glu transporter function, we measured the
extracellular concentrations of L-Glu (that is, the con-
centration of L-Glu remaining) 30 min after a single ex-
ogenous application of L-Glu to the medium (the
starting concentration was 100 μM). In this manner, we
first determined the optimal conditions for inflammation
without cell death. The cultures were treated with LPS for
72 h. The L-Glu remaining was significantly increased after
incubation with 10 and 100 ng/mL LPS (Figure 1A). Sig-
nificant LDH leakage and decreases in MTT reduction
were induced by 100 ng/mL LPS but not by LPS concen-
trations less than 10 ng/mL (Figure 1B). In pure astrocyte
cultures, significant decreases in MTT reduction were
induced by 100 ng/mL LPS, but LPS concentrations less
than 10 ng/mL did not affect either the LDH leakage or
MTT reduction (Figure 1C). Whereas increases in MTT
reduction were induced by 1 to 100 ng/mL LPS in pure
microglial culture, significant LDH leakage was induced by
100 ng/mL but not by LPS concentrations <10 ng/mL
(Figure 1D). When the treatment duration was changed,
10 ng/mL LPS was found to inhibit L-Glu uptake in a
time-dependent manner, and a significant decrease was
observed at 72 h (Figure 1E). Therefore, we adopted a 72-h
treatment with 10 ng/mL LPS for inflammation without
cell death. We also confirmed the morphology and cell
density of each cell type in this inflammation model. LPS
dramatically changed the shape of Iba-1 (+) microglia from
a ramified shape to an amoeboid shape, which is consistent
with the typical morphological changes observed after acti-
vation of microglia in previous reports [16,17] (Figure 1G).
No changes were observed in astrocytes or neurons. The
cell densities of all cell types did not change (Figure 1F).
To determine which L-Glu transporter subtypes were
responsible for the increase in the concentration of
L-Glu remaining in the mixed cultures, we first examined
the effects of various subtype-specific inhibitors on
L-Glu uptake (Figure 2A). The cultures were treated with
a non-selective L-Glu transporter inhibitor (TBOA) (10
to 1,000 μM), a GLAST-specific inhibitor (UCPH-101)
(0.1 to 10 μM), or a GLT-1-specific inhibitor (DHK) (30
to 300 μM) for 24 h, and the concentration of L-Glu
remaining in the medium 30 min after the application
of L-Glu (the starting concentration was 100 μM) in
the presence of the inhibitors was measured. TBOA
and UCPH-101 increased the L-Glu remaining in a
concentration-dependent manner to similar extents,
whereas DHK did not. These results indicate that
GLAST is the predominant functional transporter in
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Figure 1 (See legend on next page.)
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Figure 1 The concentration of L-Glu remaining was increased during inflammation without cell death. (A) Effects of LPS (1 to 100 ng/mL,
72 h) on the concentration of L-Glu remaining. The L-Glu remaining was significantly increased after incubation with 10 and 100 ng/mL LPS.
**P < 0.01 vs. control group (n = 6), Tukey’s test following an ANOVA. (B, C, D) Effects of LPS on LDH leakage and MTT reduction in the astrocyte-
microglia-neuron mixed cultures, astrocyte cultures, and microglia cultures. Significant LDH leakage and decreases in MTT reduction were induced
by 100 ng/mL LPS but not by LPS concentrations <10 ng/mL in the mixed cultures (B). In the pure astrocyte culture, LPS concentrations <10 ng/mL
affected neither LDH leakage nor MTT reduction (C). In the pure microglial culture, significant LDH leakage was induced by 100 ng/mL but not by LPS
concentrations <10 ng/mL (D). (E) Time-dependent effects of LPS. The concentration of L-Glu remaining was measured after 6 to 72-h treatments with
LPS (10 ng/mL). **P < 0.01 vs. control group (n = 6), paired t-test. (F) The effects of LPS (10 ng/mL, 72 h) on the number of neurons, astrocytes, and
microglia. LPS treatment had no effect on the cell numbers (n = 5). (G) Immunostaining of astrocytes, microglia, and neurons in the mixed culture with
antibodies against GFAP (red), Iba-1 (blue), and Tuj1 (green) after treatment with 10 ng/mL LPS for 72 h. LPS dramatically changed the shape of the
microglia from a ramified shape to an amoeboid shape.
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Figure 2 The increase in the concentration of L-Glu remaining was mainly caused by the downregulation of GLAST. (A) The effects of
TBOA (30 to 300 μM), UCPH-101 (0.1 to 10 μM), and DHK (30 to 300 μM) on L-Glu clearance. Concentration-dependent inhibition was obtained
by treatment with TBOA and UCPH-101. **P < 0.01 vs. the control group (n = 6), Tukey’s test following ANOVA. (B) The basal expression levels of
astrocyte L-Glu transporters and the effect of LPS on their expression levels. Basally, the GLAST protein level is much higher than that of GLT1.
The GLAST protein levels significantly decreased after the LPS treatment (10 ng/mL, 72 h), but GLT-1 protein levels did not change. *P < 0.05 vs.
the control group (n = 4), Student’s t-test.
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the mixed culture. We therefore examined the basal expres-
sion levels of astrocyte L-Glu transporters and the effect of
LPS on their expression levels. To compare the expression
levels of GLAST and GLT1, we first compared the densities
of western blotting bands for the same amount of GLAST
and GLT1 control proteins (full length) (1, 10 μg) obtained
at the same appropriate exposure time (Figure B, upper
photos). Then, we quantified the expression levels of
GLAST and GLT1 in the control- and LPS-treated mixed
culture (Figure B, middle photos). The density of each band
obtained at the same appropriate exposure time was nor-
malized to the 10 μg control band of the corresponding
subtype. Basally, the GLAST protein level is much higher
than that of GLT1 (Figure 2, graph). The GLAST protein
levels decreased to 65.7 ± 7.40% of control levels after LPS
treatment (10 ng/mL, 72 h) (Figure 2C), but the GLT-1
protein level did not change. These results suggest that the
LPS-induced increase in the L-Glu remaining was mainly
caused by the downregulation of GLAST.
Activated microglia caused the decrease in L-Glu uptake
during inflammation without cell death
To confirm that activated microglia are essential for the
decrease in L-Glu uptake during inflammation without
cell death, we examined the effects of LPS in four differ-
ent types of cultures, including an astrocyte-microglia-
neuron mixed culture (a), an astrocyte culture (b), an
astrocyte-microglia co-culture (c), and an astrocyte-
neuron co-culture (d) (Figure 3A). In (a), the astrocytes
were confluent, and the cell densities of the microglia
and the neurons were 3.0 × 104 cells/cm2 and 6.0 × 104
cells/cm2, respectively. Therefore, the cell density of the
microglia in (c) and that of neurons in (d) were carefully
adjusted to 3.0 × 104 cells/cm2 and 6.0 × 104 cells/cm2, re-
spectively. Furthermore, in (b) to (d), we confirmed that
the density of each cell type that had been presumably
removed was sufficiently low; the number of microglia in
(b) and (d) was <1.2 × 103 cells/cm2, and the number of
neurons in (b) and (c) was <1.0 × 103 cells/cm2. Astrocytes
LPS (ng/ml)
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Figure 3 Activated microglia are essential for the decrease in L-Glu uptake in the model of inflammation without cell death. (A)
Immunostaining of four types of cultures: astrocyte-microglia-neuron mixed culture (a), astrocyte culture (b), astrocyte-microglia co-culture (c), and
neuron-astrocyte co-culture (d). (B) The effects of LPS (10 ng/mL, 72 h) on the concentration of L-Glu remaining in the four types of culture.
Inhibitory effects were obtained in (a) and (c). **P < 0.01 vs. control group (n = 6), Student’s t-test. (C) The effects of LPS (10 ng/mL, 72 h) on the
concentration of L-Glu remaining in microglial pure culture. The concentration of L-Glu remaining did not change during the assay (30 min).
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were confluent in (a) to (d). When we treated these cul-
tures with LPS (10 ng/mL, 72 h), significant decreases in
L-Glu uptake occurred in (a) and (c) but not in (b) nor (d).
As shown in Figure 3B (b), the L-Glu uptake in astrocyte
pure culture was not changed by LPS. We further con-
firmed that in the LPS-treated microglial pure culture, the
concentration of L-Glu remaining did not change during
the assay (30 min) (Figure 3C). These results indicate that
the increase in L-Glu remaining, that is, the inhibition of
L-Glu uptake, observed in Figure 3B (a) and (c) was caused
by the interaction between the activated microglia and the
astrocytes during 72 h of LPS treatment.
L-Glu released from activated microglia caused the
downregulation of GLAST expression during
inflammation without cell death
Activated microglia release various soluble factors in
inflammatory processes [16,18-24]. To examine the in-
volvement of these factors in the action of activated
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Figure 4 Transwell carrying activated microglia, but not the conditioned medium, decreased L-Glu uptake in the astrocyte culture. (A)
Effect of the conditioned medium collected from the astrocyte-microglia-neuron mixed culture treated with LPS (10 ng/mL, 72 h) on L-Glu
clearance in the astrocyte culture. A 72-h incubation with the conditioned medium did not affect L-Glu clearance in the astrocyte culture. (B) The
effects of transwell-cultured microglia in the presence of LPS (10 ng/mL, 72 h) on L-Glu uptake in the astrocyte culture. A significant decrease in
the L-Glu uptake was caused by 72-h treatment with the transwell. **P < 0.01 vs. control group (n = 6), Student’s t-test.
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conditioned medium collected from the inflammation
without cell death model (Figure 4A) to a culture of
astrocytes alone. A 72 h-incubation with the conditioned
medium did not affect the L-Glu uptake in the astrocyte
culture. We then incubated the astrocyte culture with a
transwell on which microglia were cultured in the pres-
ence of LPS (10 ng/mL, 72 h) (Figure 4B). Notably, a sig-
nificant decrease in L-Glu uptake was obtained under
these conditions. Because LPS in this condition did not
directly affect the L-Glu uptake in the astrocyte culture,
as shown in Figure 3B (b), these results suggest that the
secreted factors are released from microglia and are
degraded or taken up after their release. ATP has been
shown to downregulate GLAST through the P2X7 re-
ceptor [28] and the ectonucleotidases of astrocytes rap-
idly convert extracellular ATP to ADP, ultimately to
AMP [34]. We first examined the contribution of ATP
to the downregulation of GLAST in the inflammation
model without cell death. Exogenous application of
ATP (Figure 5A) and P2X7 agonist BzATP (Figure 5B)
did not change the L-Glu uptake. We also confirmed
that neither the P2X receptor antagonist TNP-ATP
(Figure 5C) nor the P2X7-specific antagonist BBG
(Figure 5D) inhibited the decrease in L-Glu uptake in
this inflammation model. We then examined the possi-
bility of L-Glu. L-Glu is released by activated microglia
through hemichannels [21,22] and taken up by L-Glu
transporters after its release. We hypothesized that the
secreted factor may be L-Glu. We first examined
whether L-Glu was indeed released from microglia dur-
ing inflammation without cell death. As shown in
Figure 6A, left, LPS elevated the extracellular L-Glu con-
centrations in the astrocyte-microglia-neuron mixed cul-
tures, and a significant elevation was observed even at a
concentration of 1 ng/mL (Figure 6A left). An elevation
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Figure 5 ATP did not contribute to the downregulation of GLAST in the inflammation without cell death. (A, B) Neither ATP nor the P2X7
agonist BzATP affected L-Glu uptake. (C, D) Neither the P2X receptor antagonist TNP-ATP nor the P2X7 specific antagonist BBG affected the LPS-
induced decrease in L-Glu uptake. **P < 0.01 vs. control group (n = 6), Tukey’s test following ANOVA.






































































































































































































Figure 6 L-Glu released from activated microglia caused the downregulation of GLAST. (A) Effects of LPS (1 to 100 ng/mL, 24 h) on the
extracellular concentration of L-Glu in the astrocyte-microglia-neuron mixed culture (left), microglia culture (center), and astrocyte culture (right).
LPS significantly increased the extracellular L-Glu in the astrocyte-microglia-neuron mixed culture and the microglia culture. *P < 0.05, **P < 0.01
vs. control group (n = 6), Tukey’s test following ANOVA. (B) The effect of sustained exposure to L-Glu on L-Glu clearance in the astrocyte culture.
The culture medium was changed to fresh medium containing 100 μM L-Glu every 2 h. L-Glu clearance was suppressed by sustained exposure to
L-Glu for 24 h. **P < 0.01 vs. the control group (n = 6), Student’s t-test. (C) The effect of sustained exposure to L-Glu on GLAST mRNA levels.
Sustained exposure to L-Glu decreased GLAST mRNA. **P < 0.01 vs. control group (n = 4), Student’s t-test. (D) The effect of sustained exposure to
L-Glu on GLAST protein levels. Sustained exposure to L-Glu decreased the protein expression of GLAST. **P < 0.01 vs. control group (n = 5),
Student’s t-test.
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the microglia culture (Figure 6A center) but not in the
astrocyte culture (Figure 6A right). These results indi-
cate that L-Glu was released from activated microglia
during inflammation without cell death. To confirm our
hypothesis, we tested the effect of the sustained eleva-
tion of extracellular L-Glu on L-Glu uptake in the mixed
culture. To yield a sustained elevation of extracellular
L-Glu, the culture medium of the astrocyte culture was
freshly supplemented with 100 μM L-Glu every 2 h for
24 h, as preliminary studies showed that a concentration
of 100 μM extracellular L-Glu was reduced to almost
zero after 4 h in confluent astrocyte cultures (not
shown). As shown in Figure 6B, the sustained elevation
of extracellular L-Glu resulted in a significant decrease
in L-Glu uptake in the astrocyte culture. GLAST expres-
sion was significantly decreased at the mRNA level























































































































































Figure 7 CBX ameliorated the decrease in L-Glu uptake and GLAST expression in inflammation without cell death. (A) The effect of CBX
on L-Glu release from activated microglia. CBX concentration-dependently suppressed L-Glu release due to LPS (10 ng/mL, 24 h)-activated
microglia. **P < 0.01 vs. control group, #P < 0.05, ##P < 0.01 vs. the LPS-treated group (n = 5), Tukey’s test following ANOVA. (B) The effects of CBX
on the decreased L-Glu uptake in the model of inflammation without cell death. CBX concentration-dependently inhibited the LPS (10 ng/mL, 72 h)-
induced decrease in L-Glu uptake in the astrocyte-microglia-neuron mixed culture (left) but not in the astrocyte culture (right). **P < 0.01 vs. control
group, #P < 0.05, ##P <0.01 vs. the LPS-treated group (n = 5), Tukey’s test following ANOVA. (C) The effect of CBX on the LPS-induced decrease in
GLAST mRNA levels. In the presence of CBX (100 μM), the LPS (10 ng/mL, 24 h)-induced decrease in GLAST mRNA level was ameliorated in the
astrocyte-microglia-neuron mixed culture. **P < 0.01 vs. control group, #P < 0.05 vs. the LPS-treated group (n = 5), Tukey’s test following ANOVA. (D) The
effect of CBX on the LPS-induced decrease in GLAST protein levels. In the presence of CBX (100 μM), the LPS (10 ng/mL, 72 h)-induced decrease in
GLAST protein levels was ameliorated in the astrocyte-microglia-neuron mixed culture. *P < 0.05 vs. control group (n = 4), Tukey’s test following ANOVA.
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(Figure 6C) and the protein level (Figure 6D) by the
same treatment. These results suggest that L-Glu was re-
sponsible for the decrease in L-Glu uptake during in-
flammation without cell death. When the microglia
cultures were treated with LPS (10 ng/mL, 24 h) in the
absence or presence of the hemichannel inhibitor, CBX
(10 to 100 μM), the L-Glu release from the activated
microglia was suppressed in a concentration-dependent
manner (Figure 7A). CBX (100 μM) almost completely
prevented the LPS-induced (10 ng/mL, 72 h) decrease in
L-Glu uptake in the mixed culture (Figure 7B, left) but
had no effect in the astrocyte culture (Figure 7B, right).
Furthermore, CBX reversed the LPS-induced down-
regulation of GLAST expression at the mRNA
(Figure 7C) and protein levels (Figure 7D).
We next tried to clarify the mechanisms through
which the sustained elevation of extracellular L-Glu
downregulates GLAST. Recent reports have suggested
that the expression of L-Glu transporters is regulated
by L-Glu through metabotropic glutamate receptors
(mGluRs). We therefore first examined the involvement
of metabotropic glutamate receptors (mGluRs). Neither
the group I mGluR agonist DHPG nor the group II
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Figure 8 The elevation of intracellular L-Glu in astrocytes is important for the downregulation of GLAST. (A, B) The effects of mGluR
agonists on L-Glu uptake. Neither the group I mGluR agonist DHPG (A) nor the group II mGluR agonist DCG-4 (B) affected L-Glu uptake. (C) The
amount of astrocytic intracellular L-Glu after LPS-treatment in the absence or presence of TBOA in astrocyte-microglia co-cultures. LPS
significantly increased the amount of astrocytic intracellular L-Glu, and TBOA completely suppressed this increase. **P < 0.01 vs. control group,
##P < 0.01 vs. the LPS-treated group (n = 6), Tukey’s test following ANOVA. (D) The astrocytic expression of GLAST after LPS treatment in the
absence or presence of TBOA in astrocyte-microglia co-cultures. TBOA suppressed the downregulation GLAST caused by LPS. *P < 0.05 vs. control
group, #P < 0.05 vs. the LPS-treated group (n = 6), Tukey’s test following ANOVA.
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(Figure 8A and B) or the expression level of GLAST
(not shown). Sustained elevation of extracellular L-Glu
caused by activated microglia is expected to cause the
elevation of intracellular L-Glu in astrocytes. We there-
fore examined whether the elevation of intracellular
L-Glu itself is important for the downregulation of
GLAST. To do this, we first measured the amount of
astrocytic intracellular L-Glu after LPS-treatment in the
absence or presence of TBOA in astrocyte-microglia co-
cultures (Figure 8C). LPS significantly increased the
amount of intracellular L-Glu, and TBOA completely
suppressed this increase. Western blotting showed that
TBOA suppressed the downregulation GLAST caused
by LPS (Figure 8D). TBOA itself did not have effects on
either the amount of intracellular L-Glu or the GLAST
protein level. These results indicate that the elevation of
astrocytic intracellular L-Glu, but not the signaling cas-
cade from the cell surface, is important for the downre-
gulation of GLAST.
Our findings suggest that activated microglia trigger
the elevation of extracellular L-Glu through their own
release of L-Glu, astrocyte L-Glu transporters are down-
regulated by the elevation of astrocytic intracellular
L-Glu, and further elevation of extracellular L-Glu occurs
early in neuroinflammation. A schematic model of this
‘collusion’ hypothesis is shown in Figure 9.
Discussion
To quantify L-Glu transporter function, we measured
the extracellular concentrations of L-Glu 30 min after a
single exogenous application of L-Glu to the medium
(the starting concentration was 100 μM). To limit any
contributions of extra L-Glu from dying cells, and to
verify a substantial contribution of the decrease in L-Glu
transport potency to an elevated concentration of extra-
cellular L-Glu in inflammation, we first determined the
optimal conditions for inflammation without cell death.
We used a lower concentration of LPS (10 ng/mL) than
is generally used [35,36]. LPS application at a concentra-
tion of 10 ng/mL for 72 h activated the microglia but
did not cause either LDH leakage or decreases in MTT
reduction in the mixed culture, astrocyte pure culture,
or microglia pure culture. LPS induces an inflammatory
response in microglia via Toll-like receptor 4 (TLR4)
[37]. TLR4 is also expressed by astrocytes, and astrocytes
themselves have shown inflammatory responses in re-
sponse to LPS in some reports [38]. In the present study,
however, microglia were essential for the decreased
L-Glu by astrocytes, and LPS did not affect L-Glu uptake
in astrocyte cultures. Because the expression of TLR4 by
astrocytes is less than that of microglia [37], the LPS
stimulation in our model of inflammation without cell
death may be insufficient to induce phenotypic changes
in astrocytes. These mild inflammatory conditions may
reflect the early stages of neuroinflammation in vivo, in
which early microglial activation has been observed to
precede the phenotypic changes in astrocytes [39].
In the present study, we pharmacologically con-
firmed that GLAST, and not GLT-1, was the predom-
inant functional L-Glu transporter. We also confirmed
that the expression level of GLT-1 is much lower than
that of GLAST. GLT-1 has been reported to be func-
tional in neuron-astrocyte co-cultures at 32 to 44 DIV
[40]. This discrepancy most likely arises from the
maturation stages of neurons, as the functional devel-
opment of GLT-1 correlates with neuronal maturation
[41]. The expression of GLAST was significantly
decreased in the ‘non-cell death inflammation model’,
which indicates that the decrease in L-Glu uptake in

















early stage of 
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Figure 9 Schematic model of the ‘collusion’ hypothesis for the
elevation of extracellular L-Glu in the early stages of
inflammation.1. Activated microglia release L-Glu. 2. The
resultant elevation of extracellular L-Glu causes the elevation of
astrocytic intracellular L-Glu. 3. The elevation of astrocytic
intracellular L-Glu downregulates GLAST expression. 4. The
decrease in GLAST expression further exacerbates the elevation of
extracellular L-Glu.
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Activated microglia release various soluble factors, in-
cluding inflammatory cytokines [18,19], reactive oxygen
species [20], NO [16], L-Glu [21,22], and ATP [23,24].
We demonstrated that L-Glu is the factor that downre-
gulates GLAST in astrocytes during inflammation with-
out cell death. Although activated microglia are known
to release L-Glu through hemichannels [21,22], the
neurological importance of this phenomenon remains
unclear. We showed that the hemichannel inhibitor
CBX completely suppressed the release of L-Glu from
microglia, the decrease in L-Glu uptake, and the down-
regulation of GLAST expression during inflammation
without cell death. These data provide strong evidence
that L-Glu is the microglial releasing factor that downre-
gulates GLAST. High concentrations of ATP have also
been shown to downregulate GLAST through the P2X7
receptor [28]. However, we believe that ATP did not
contribute to the down-regulation of GLAST in the in-
flammation model without cell death here because
L-Glu uptake did not change when the astrocyte culture
was treated with ATP (Figure 5A) or the P2X7 agonist
BzATP (Figure 5B). We also confirmed that neither the
P2X receptor antagonist TNP-ATP (Figure 5C) nor the
P2X7-specific antagonist BBG (Figure 5D) inhibited the
decrease in L-Glu uptake in this inflammation model.
Other microglial releasing factors, such as TNF-α, IL-1β,
and arachidonic acid, are also known to decrease the
L-Glu transport in astrocyte cultures [25-27]. However,
the conditioned media collected from our model of in-
flammation without cell death had no effect in the astro-
cyte culture. Because the LPS stimulation here was lower
than that of other studies [35,36] (to prevent cell death),
the amount of these factors in the conditioned media
may have been insufficient to affect L-Glu transporters.
Recent reports have suggested that the expression of
L-Glu transporters is regulated by L-Glu through meta-
botropic glutamate receptors (mGluRs), that is, the
group I mGluR agonist downregulates GLAST, whereas
the group II mGluR agonist has the opposite effect
[42,43]. However, neither the group I mGluR agonist nor
the group II mGluR agonist affected the expression of
GLAST in the present study. Instead, we clarified that
the elevation of intracellular L-Glu in astrocytes is im-
portant for the downregulation of GLAST as shown in
Figure 8. It has been clarified that translation initiation
is regulated by intracellular L-Glu transported by
GLAST in Bergmann glial cells [44,45]. They also
showed that mammalian target of rapamycin (mTOR),
increase in intracellular Ca2+ levels, and p60(Src)/PI3K/
PKB pathway are involved in this regulation. Further in-
vestigation is necessary to confirm whether the same
pathways are involved in the downregulation of GLAST
observed in our study. Of interest, a sustained elevation
of extracellular L-Glu induced by the same protocol as
Figure 6 did not cause the downregulation of glutamine
synthetase (GS) in our preliminary experiment (data not
shown), suggesting that this regulation is GLAST or
L-Glu transporter-specific. The comparison of the up-
stream DNA sequences of GLAST and GS might provide
useful information. Besides, in Saccharomyces cerevisiae,
the activator (NIL1p) of the amino acid transporter is
inactivated by increases in intracellular glutamate [46]. It
is possible that a conserved mechanism similar to this
also exist in astrocytes. Our findings strongly suggest
that L-Glu is the microglial releasing factor which results
in downregulation of GLAST in the early stage of inflam-
mation. However, whether or not the quantity of L-Glu
released from microglia is enough to induce a range of
reaction still needs to be elucidated. Based on the discus-
sion above, the co-factors to enhance the signaling path-
way in the astrocytes leading to the downregulation of
GLAST might be also released from microglia.
Conclusions
Our findings suggest that activated microglia trigger the
elevation of extracellular L-Glu through their own re-
lease of L-Glu, astrocyte L-Glu transporters are downre-
gulated by the elevation of astrocytic intracellular L-Glu,
and further elevation of extracellular L-Glu is caused as
an early event of neuroinflammation (Figure 9).
Abbreviations
ANOVA: Analysis of variance; ATP: Adenosine 50-triphosphate disodium salt
hydrate; BPB: Bromophenol blue sodium salt; BSA: Albumin bovine serum;
BzATP: 20 (30)-O-(4-Benzoylbenzoyl)ATP triethylammonium salt;
CBX: Carbenoxolone; CNS: Central nervous system; DHK: Dihydrokainic acid;
DIV: Days in vitro; DMEM: Dulbecco’s modified eagle medium;
DNA: Deoxyribonucleic acid; EDTA: Ethylenediaminetetraacetate;
EGTA: Ethyleneglycoldiaminetetraacetate; FBS: Fetal bovine serum; GFAP: Glial
fibrillary acidic protein; GlDH: Glutamate dehydrogenase; HS: Horse serum;
LDH: Lactate dehydrogenase; L-Glu: L-glutamate; LPS: Lipopolysaccharide;
mGluRs: Metabotropic glutamate receptors; MPMS: 1-methoxy-5-methyl-
phenazinium methyl sulfate; MTT: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide; β-NAD: β-nicotinamide adenine dinucleotide;
NO: Nitric oxide; NP-40: Polyoxyethylene(9)octylphenyl ether;
OxATP: Adenosine 50-triphosphate periodate oxidized sodium salt;
PBS: Phosphate-buffered saline; PFA: Paraformaldehyde; RNA: Ribonucleic
acid; RT-PCR: Polymerase chain reaction; SD: Sprague–Dawley; SDS: Sodium
dodecyl sulfate; TBOA: DL-threo-β-benzyloxyaspartic acid; TLR4: Toll-like
receptor 4; TNP-ATP: 20,30-O-(2,4,6-Trinitrophenyl)ATP salt hydrate; Tris–




I declare that I have no significant competing financial, professional or
personal interests that might have influenced the performance or
presentation of the work described in this manuscript.
Authors’ contributions
JT performed experimental work and manuscript writing. KF performed
experimental work. MM performed additional experimental work. TS
provided advice on the experimental direction. YS provided advice on
manuscript writing and preparation. KS designed the biological experimental
plan and performed biological experiments, data analysis, manuscript
writing, and preparation. All authors have read and approved the final
version of the manuscript.
Takaki et al. Journal of Neuroinflammation 2012, 9:275 Page 15 of 17
http://www.jneuroinflammation.com/content/9/1/275
Acknowledgements
This study was partly supported by a Grant-in-Aid from the Food Safety
Commission of Japan (No. 1003); a Grant-in-Aid for Young Scientists from
MEXT, Japan (KAKENHI 21700422); the Program for the Promotion of
Fundamental Studies in Health Sciences of NIBIO, Japan; a Health and Labor
Science Research Grant for Research on Risks of Chemicals; and a Health and
Labor Science Research Grant for Research on New Drug Development from
MHLW, Japan, awarded to KS and YS.
Author details
1Laboratory of Neuropharmacology, Division of Pharmacology, National
Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501,
Japan. 2Division of Basic Biological Science, Faculty of Pharmacy, Keio
University, 1-5-30 Shiba-koen, Minato-ku, Tokyo 105-8512, Japan.
Received: 25 May 2012 Accepted: 1 December 2012
Published: 23 December 2012
References
1. Kumar A, Singh RL, Babu GN: Cell death mechanisms in the early stages
of acute glutamate neurotoxicity. Neurosci Res 2010, 66:271–278.
2. Choi DW: Glutamate neurotoxicity and diseases of the nervous system.
Neuron 1988, 1:623–634.
3. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai
Y, Hediger MA, Wang Y, Schielke JP, Welty DF: Knockout of glutamate
transporters reveals a major role for astroglial transport in excitotoxicity
and clearance of glutamate. Neuron 1996, 16:675–686.
4. Lauderback CM, Harris-White ME, Wang Y, Pedigo NW Jr, Carney JM,
Butterfield DA: Amyloid beta-peptide inhibits Na+-dependent glutamate
uptake. Life Sci 1999, 65:1977–1981.
5. Rothstein JD: Excitotoxicity and neurodegeneration in amyotrophic
lateral sclerosis. Clin Neurosci 1995–1996, 3:348–359.
6. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM,
Bunney WE Jr, Akil H, Watson SJ, Jones EG: Altered cortical glutamatergic
and GABAergic signal transmission with glial involvement in depression.
Proc Natl Acad Sci USA 2005, 102:15653–15658.
7. Beart PM, O’Shea RD: Transporters for L-glutamate: an update on their
molecular pharmacology and pathological involvement. Br J Pharmacol
2007, 150:5–17.
8. Guo F, Sun F, Yu JL, Wang QH, Tu DY, Mao XY, Liu R, Wu KC, Xie N, Hao LY,
Cai JQ: Abnormal expressions of glutamate transporters and
metabotropic glutamate receptor 1 in the spontaneously epileptic rat
hippocampus. Brain Res Bull 2010, 81:510–516.
9. Rakhade SN, Loeb JA: Focal reduction of neuronal glutamate transporters
in human neocortical epilepsy. Epilepsia 2008, 49:226–236.
10. Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MG, Schrama LH,
van Veelen CW, van Rijen PC, van Nieuwenhuizen O, Gispen WH, de Graan
PND: Distribution of glutamate transporters in the hippocampus of
patients with pharmaco-resistant temporal lobe epilepsy. Brain 2002,
125:32–43.
11. Ward RJ, Colivicchi MA, Allen R, Schol F, Lallemand F, de Witte P, Ballini C,
Corte LD, Dexter D: Neuro-inflammation induced in the hippocampus of
‘binge drinking’ rats may be mediated by elevated extracellular
glutamate content. J Neurochem 2009, 111:1119–1128.
12. Castillo J, Dávalos A, Alvarez-Sabín J, Pumar JM, Leira R, Silva Y, Montaner J,
Kase CS: Molecular signatures of brain injury after intracerebral
hemorrhage. Neurology 2002, 58:624–629.
13. Allen NJ, Barres BA: Neuroscience: Glia - more than just brain glue. Nature
2009, 457:675–677.
14. Lehnardt S: Innate immunity and neuroinflammation in the CNS: the role
of microglia in Toll-like receptor-mediated neuronal injury. Glia 2010,
58:253–263.
15. Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease.
Nat Rev Neurol 2010, 6:193–201.
16. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.
Trends Neurosci 1996, 19:312–318.
17. Lynch MA: The multifaceted profile of activated microglia. Mol Neurobiol
2009, 40:139–156.
18. Hanisch UK: Microglia as a source and target of cytokines. Glia 2002,
40:140–155.
19. Nakajima K, Kohsaka S: Microglia: activation and their significance in the
central nervous system. J Biochem 2001, 130:169–175.
20. Block ML, Hong JS: Chronic microglial activation and progressive
dopaminergic neurotoxicity. Biochem Soc Trans 2007, 35:1127–1132.
21. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y,
Mizuno T, Suzumura A: Tumor necrosis factor-alpha induces neurotoxicity
via glutamate release from hemichannels of activated microglia in an
autocrine manner. J Biol Chem 2006, 281:21362–21368.
22. Yawata I, Takeuchi H, Doi Y, Liang J, Mizuno T, Suzumura A:
Macrophage-induced neurotoxicity is mediated by glutamate and
attenuated by glutaminase inhibitors and gap junction inhibitors.
Life Sci 2008, 82:1111–1116.
23. Higashi Y, Segawa S, Matsuo T, Nakamura S, Kikkawa Y, Nishida K, Nagasawa
K: Microglial zinc uptake via zinc transporters induces ATP release and
the activation of microglia. Glia 2011, 59:1933–1945.
24. Kim SY, Moon JH, Lee HG, Kim SU, Lee YB: ATP released from beta-
amyloid-stimulated microglia induces reactive oxygen species
production in an autocrine fashion. Exp Mol Med 2007, 39:820–827.
25. Carmen J, Rothstein JD, Kerr DA: Tumor necrosis factor-alpha modulates
glutamate transport in the CNS and is a critical determinant of outcome
from viral encephalomyelitis. Brain Res 2009, 1263:143–154.
26. Prow NA, Irani DN: The inflammatory cytokine, interleukin-1 beta,
mediates loss of astroglial glutamate transport and drives excitotoxic
motor neuron injury in the spinal cord during acute viral
encephalomyelitis. J Neurochem 2008, 105:1276–1286.
27. Volterra A, Trotti D, Racagni G: Glutamate uptake is inhibited by
arachidonic acid and oxygen radicals via two distinct and additive
mechanisms. Mol Pharmacol 1994, 46:986–992.
28. Liu YP, Yang CS, Chen MC, Sun SH, Tzeng SF: Ca(2+)-dependent reduction
of glutamate aspartate transporter GLAST expression in astrocytes by
P2X(7) receptor-mediated phosphoinositide 3-kinase signaling.
J Neurochem 2010, 113:213–227.
29. Sato K, Matsuki N, Ohno Y, Nakazawa K: Estrogens inhibit l-glutamate
uptake activity of astrocytes via membrane estrogen receptor alpha.
J Neurochem 2003, 86:1498–1505.
30. Sato K, Saito Y, Oka J, Ohwada T, Nakazawa K: Effects of tamoxifen on
L-glutamate transporters of astrocytes. J Pharmacol Sci 2008, 107:226–230.
31. Nakajima K, Shimojo M, Hamanoue M, Ishiura S, Sugita H, Kohsaka S:
Identification of elastase as a secretory protease from cultured rat
microglia. J Neurochem 1992, 58:1401–1408.
32. Kohl A, Dehghani F, Korf HW, Hailer NP: The bisphosphonate clodronate
depletes microglial cells in excitotoxically injured organotypic
hippocampal slice cultures. Exp Neurol 2003, 181:1–11.
33. Abe K, Matsuki N: Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate
dehydrogenase release using MTT. Neurosci Res 2000, 38:325–329.
34. Wink MR, Braganhol E, Tamajusuku AS, Lenz G, Zerbini LF, Libermann
TA, Sévigny J, Battastini AM, Robson SC: Nucleoside triphosphate
diphosphohydrolase-2 (NTPDase2/CD39L1) is the dominant
ectonucleotidase expressed by rat astrocytes. Neuroscience 2006,
138:421–432.
35. Li J, Ramenaden ER, Peng J, Koito H, Volpe JJ, Rosenberg PA: Tumor
necrosis factor alpha mediates lipopolysaccharide-induced microglial
toxicity to developing oligodendrocytes when astrocytes are present.
J Neurosci 2008, 28:5321–5330.
36. Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by
nitric oxide from activated glia-inhibiting neuronal respiration, causing
glutamate release and excitotoxicity. J Neurosci 2001, 21:6480–6491.
37. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE,
Rosenberg PA, Volpe JJ, Vartanian T: The toll-like receptor TLR4 is
necessary for lipopolysaccharide-induced oligodendrocyte injury in the
CNS. J Neurosci 2002, 22:2478–2486.
38. Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD:
Differential activation of astrocytes by innate and adaptive immune
stimuli. Glia 2005, 49:360–374.
39. Tilleux S, Hermans E: Neuroinflammation and regulation of glial glutamate
uptake in neurological disorders. J Neurosci Res 2007, 85:2059–2070.
40. Swanson RA, Liu J, Miller JW, Rothstein JD, Farrell K, Stein BA: Longuemare
MC: Neuronal regulation of glutamate transporter subtype expression in
astrocytes. J Neurosci 1997, 17:932–940.
Takaki et al. Journal of Neuroinflammation 2012, 9:275 Page 16 of 17
http://www.jneuroinflammation.com/content/9/1/275
41. Perego C, Vanoni C, Bossi M, Massari S, Basudev H, Longhi R, Pietrini G: The
GLT1 and GLAST glutamate transporters are expressed on
morphologically distinct astrocytes and regulated by neuronal activity in
primary hippocampal cocultures. J Neurochem 2000, 75:1076–1084.
42. Gegelashvili G, Dehnes Y, Danbolt NC, Schousboe A: The high-affinity
glutamate transporters GLT1, GLAST, and EAAT4 are regulated via
different signalling mechanisms. Neurochem Int 2000, 37:163–170.
43. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S,
Troost D: Expression and functional role of mGluR3 and mGluR5 in
human astrocytes and glioma cells: opposite regulation of glutamate
transporter proteins. Eur J Neurosci 2003, 17:2106–2118.
44. González-Mejia ME, Morales M, Hernández-Kelly LC, Zepeda RC, Bernabé A,
Ortega A: Glutamate-dependent translational regulation in cultured
Bergmann glia cells: involvement of p70S6K. Neuroscience 2006,
141:1389–1398.
45. Zepeda RC, Barrera I, Castelán F, Suárez-Pozos E, Melgarejo Y, González-Mejia E,
Hernández-Kelly LC, López-Bayghen E, Aguilera J, Ortega A: Glutamate-
dependent phosphorylation of the mammalian target of rapamycin (mTOR)
in Bergmann glial cells. Neurochem Int 2009, 55:282–287.
46. Stanbrough M, Rowen DW, Magasanik B: Role of the GATA factors Gln3p
and Nil1p of Saccharomyces cerevisiae in the expression of nitrogen-
regulated genes. Proc Natl Acad Sci USA 1995, 92:9450–9454.
doi:10.1186/1742-2094-9-275
Cite this article as: Takaki et al.: L-glutamate released from activated
microglia downregulates astrocytic L-glutamate transporter expression
in neuroinflammation: the ‘collusion’ hypothesis for increased
extracellular L-glutamate concentration in neuroinflammation. Journal of
Neuroinflammation 2012 9:275.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Takaki et al. Journal of Neuroinflammation 2012, 9:275 Page 17 of 17
http://www.jneuroinflammation.com/content/9/1/275
